You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The consortium, recently funded with €750,000, is developing a computational tool for identifying NAFLD patients at high risk of progressing to NASH.
Called CoronaDx, which has a budget of €3 million, aims to facilitate the development of testing systems for use in remote areas with limited infrastructure.
The test could also be used to assess vaccine effectiveness, should a vaccine become available.
A consortium led by the Barcelona-based company recently received €150,000 in EU funding to bring the platform to market.
The effort, called INNO4COV-19, was awarded €6.1 million last month to support the commercialization of new diagnostics.
The effort is one of 23 research projects selected as part of a new, €128 million EU package to combat COVID-19.
Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.
While results are preliminary, the test could potentially be used in lieu of a liver biopsy.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.